TS
ANIP icon

Thomas Steyer’s ANI Pharmaceuticals ANIP Stock Holding History

Thomas Steyer’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$941K – 98
2014
Q1 		$941K Buy
+30,000
New +$796K 0.02% 81

Other funds holding ANIP

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.71B AUM 65.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return

Thomas Steyer's ANIP Position: Q2 2014 in Review

Thomas Steyer sold out of ANI Pharmaceuticals (ANIP) in Q2 2014, closing a stake of 30,000 shares — an estimated $941K sold.

Thomas Steyer first reported a position in ANIP in Q1 2014 and held it in 1 quarter. The position peaked at $941K in Q1 2014. 81 funds tracked by Wall St. Rank hold ANIP as of Q2 2014.

  • Thomas Steyer reported no remaining ANI Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Thomas Steyer sold 30,000 ANI Pharmaceuticals shares in Q2 2014, an estimated $941K.
  • Thomas Steyer first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Thomas Steyer's ANI Pharmaceuticals position peaked at $941K in Q1 2014.
  • 81 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2014.

Based on Farallon Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.